Back to News
Feb 9, 2026 8:10 AM

Aerska Raises $39M Series A Financing led by EQT Dementia Fund and age1 to Systemically Deliver RNA Medicines to the Brain

Brings total funds raised to $60 million since launch, months after itsĀ seed funding announcement in October 2025

Appoints Arno de Wilde, Philip Scheltens and Alex Colville to its Board of Directors

DUBLIN and LONDON, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Aerska, a biotechnology company using brain shuttle technology to develop RNA medicines for CNS diseases, today announced the close of a $39 million Series A financing led by EQT Dementia Fund and age1, with participation from Iaso Ventures, alongside existing investors. The funding will be used to advance its brain shuttle technology to improve delivery of RNAi interference (RNAi) therapeutics across the blood-brain barrier for treating neurological diseases.

This brings total funds raised to $60 million to-date, months after its seed funding announcement in October 2025. Proceeds will support continued development of Aerska's antibody-oligo conjugate (AOC) ...